

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 43/40	A1	(11) International Publication Number: WO 99/00019 (43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: PCT/US98/13460 (22) International Filing Date: 26 June 1998 (26.06.98) (30) Priority Data: 60/051,120 27 June 1997 (27.06.97) US (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): MACDONALD, Brian, R. [US/US]; 10 Liberty Lane, Valley Forge, PA 19481 (US). (74) Agents: VENETIANER, Stephen et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHODS OF TREATING THE SYMPTOMS OF ATROPHIC VAGINITIS AND ALTERED SEXUAL BEHAVIOR IN POSTMENOPAUSAL WOMEN (57) Abstract A novel method for treating the symptoms of atrophic vaginitis and altered sexual behavior in postmenopausal women is described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS OF TREATING THE SYMPTOMS OF ATROPHIC VAGINITIS AND ALTERED SEXUAL BEHAVIOR IN POSTMENOPAUSAL WOMEN

Field of the Invention

5 The present invention relates to therapeutic agents that bind to the estrogen receptor and cause tissue specific estrogen agonist effects, that have been found to be useful in the treatment of the symptoms of atrophic vaginitis and altered sexual behavior in postmenopausal women.

10 Background of the Invention


Menopause and the perimenopause in women (also known as the climacteric) are often marked by the occurrence of symptoms relating to loss of estrogen stimulated vaginal secretions (atrophic vaginitis). Alterations in sexual behavior are also common at the time
15 of the menopause. The standard treatment for these symptoms is hormone replacement therapy (HRT) which may be given topically for the relief of vaginal symptoms. This use of HRT is not without controversy. Questions have arisen as to whether estrogen replacement should be continued beyond one to two years. There appears to be an increased risk of breast and endometrial cancer with the long term use of estrogen
20 replacement therapy. Additionally, short term side-effects of HRT include weight gain, breast tenderness and vaginal bleeding. For a more detailed discussion of the effects of HRT see Valda et al. (1994). Hormonal Treatment for the Climacteric: Alleviation of Symptoms and Prevention of Postmenopausal Disease, The Lancet, vol. 343, pages 654-658.

25

Summary of the Invention

This invention provides a method for the prevention and treatment of the symptoms of atrophic vaginitis and altered sexual behavior in postmenopausal women without the side
30 effects of Hormonal Replacement Therapy (HRT). The method comprises administering to a human in need thereof an effective amount of a therapeutic agent that binds to the estrogen receptor and produces a tissue specific estrogen agonist effect in the vaginal and cervical glandular/epithelial cells or the specific areas of the brain that control sexual

behavior. Specifically, compounds that can be utilized in this invention are compounds of formula I



(I)

5 wherein X represents 3- or 4- iodo or bromo and the R¹ and R² symbols, which may be the same or different, represent C₁₋₃ alkyl, especially methyl or ethyl, groups or R¹ represents a hydrogen atom and R² a C₁₋₃ alkyl group or R¹ and R² together with the nitrogen atom to which they are attached represent a saturated heterocyclic group, typically having 5 or 6
 10 ring atoms, especially a pyrrolidino, piperidino, 4-methylpiperidino or morpholino group, and their pharmaceutically acceptable acid addition salts. Preferred is the compound known as idoxifene.


Detailed Description of the Invention

15 The present invention is a therapeutic method for treating the symptoms of atrophic vaginitis and altered sexual behavior in postmenopausal women with agents that bind to the estrogen receptor and, as a consequence of that interaction with the estrogen receptor, cause either estrogenic (estrogen agonist) or antiestrogenic (estrogen antagonist) effects in
 20 different tissues. Thus the same agent may be estrogenic in one tissue but antiestrogenic in another. Some compounds of this description are in clinical use because of the beneficial effects that are produced in specific tissues as a result of binding to the estrogen receptor (for example the use of the antiestrogenic effects of tamoxifen in breast tissue to provide therapeutic benefit in the treatment of breast cancer). The preferred effect of a compound
 25 for the desired method of treatment is to produce estrogenic effects in the vaginal epithelial and cervical glandular cells or the specific areas of the brain that control sexual behavior. This would have the clinical effect of reducing the severity of vaginal itching and dryness, pain on sexual intercourse and decreased libido by having the same effect as estrogen in

these tissues. An example of such a compound is idoxifene. Preferred compounds are described in formula I above and in U.S. patent 4,839,155.

The preferred compound for the described method of treatment is

5



(E)-1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]pyrrolidine
(Idoxifene)

10 The symptoms that would be treated in this invention are an important component of a menopausal syndrome that also includes vasomotor symptoms (hot flashes), sleep disturbance, agitation, nervousness, mood changes, anxiety, irritability, loss of memory and concentration, crying spells, tiredness, depression, headache, and joint or muscle pain. For a more detailed discussion of this phenomenon, please see Oldenhave A., Jaszman LJB, 15 Haspels AA, Everaerd W Th AM, Impact of climacteric on well-being, Am J Obstet Gynecol, 1993; 168: 772-80. The cause of the increase in symptoms of atrophic vaginitis at the time of the menopause is the loss of estrogen (as a result of ovarian failure) which causes the mucus producing cells of the vaginal epithelium and cervix to become atrophic. This effects may last for many years after the menopause. Additionally the lack of estrogen 20 affects the function of the areas of the brain that control sexual behavior. Thus many patients experience a decrease in libido at the time of the menopause.

In a study in ovariectomized cynomologous monkeys idoxifene caused a dose related protection from the loss of vaginal epithelial stratification/cornification and cervical mucus secretion that was observed in the ovariectomized control animals.

25 A double-blind placebo controlled trial of three doses of Idoxifene (tablet strengths were 2.5, 5.0 and 10 mgs) given daily for four weeks was performed to test the effect of idoxifene in patients with moderate or severe vasomotor symptoms. A questionnaire was also administered to the patients to provide information about the severity of the other

symptoms that comprise the menopausal syndrome including those that would be treated in this invention. A loading dose regimen was employed which involved taking three tablets as a single daily dose for the first week and one tablet per day thereafter. Analysis of the data from the patient questionnaire revealed that the responses to the questions on sexual function were significantly improved from baseline in the group of patients who received 5mg/day of idoxifene.

The data from the above analysis were as follows:

10	Placebo (n= 40)	5.0 mg/day (n= 39)
	22.2%	34.2%

The above figures represent the percentage improvement in the scores of response to the specific questions relating to sexual function compared to responses to the same questions before treatment. The differences from baseline were statistically significant (p<0.05).

In a second study testing three months of treatment with the same doses of idoxifene in postmenopausal women the percentage of subjects reporting leukorrhoea, indicating a return of physiological vaginal secretions, was as follows:

20	Placebo	2.5mg/day	5.0mg/day	10.0mg/day
	4%	24%	12%	17%

The compounds of the instant invention and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example, polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or coloring agent.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example
5 aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

The compounds of the instant invention and their pharmaceutically acceptable salts which are active when administered parenterally (i.e. by injection or infusion) can be formulated as solutions or suspensions.

10 A composition for parenteral administration will generally consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

15 A typical suppository composition comprises a compound of the instant invention or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.

A typical transdermal formulation comprises a conventional aqueous or non-
20 aqueous vehicle, for example, a cream, ointment lotion or paste or in the form of a medicated plaster, patch or membrane.

For topical administration, the pharmaceutical compositions adapted include solutions, suspensions, ointments, and solid inserts. Typical pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as
25 lower alkanols or vegetable oils, and water soluble ophthalmologically acceptable non-toxic polymers, for example, cellulose derivatives such as methyl cellulose. The pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting and bodying agents, as for example, polyethylene glycols; antibacterial components such as quaternary ammonium compounds; buffering ingredients
30 such as alkali metal chloride; antioxidants such as sodium metabisulfite; and other conventional ingredients such as sorbitan monolaurate.

Preferably the composition is in unit dose form. Doses of the compounds of the instant invention in a pharmaceutical dosage unit will be an efficacious, non-toxic quantity

- selected from the range of .01 - 200 mg/kg of active compound, preferably .1 - 100 mg/kg. The selected dose is administered to a human patient in need of treatment for vasomotor symptoms from 1-6 times daily, orally, rectally, topically, by injection, or continuously by infusion. Oral dosage units for human administration preferably contain from 10 to 500 mg of active compound. Lower dosages are used generally for parenteral administration. Oral administration is used when safe, effective, and convenient for the patient.

No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.

Example 1

- 10 An oral dosage form for administering orally active Formula (I) compounds is produced by screening, mixing and filling into hard gelatin capsules the ingredients in proportions, for example, as shown below.

	<u>Ingredients</u>	<u>Amounts</u>
15	(E)-1-[2-[4-[1-(4-Iodophenyl)-2-phenyl-1-butenyl]phenoxy]pyrrolidine	100 mg
	magnesium stearate	10 mg
	lactose	100 mg

- 20 Example 2

The sucrose calcium sulfate dihydrate and orally active Formula (I) compounds are mixed and granulated with a 10% gelating solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

	<u>Ingredients</u>	<u>Amounts</u>
25	(E)-1-[2-[4-[1-(4-Iodophenyl)-2-phenyl-1-butenyl]phenoxy]pyrrolidine	75 mg
	calcium sulfate dihydrate	100 mg
	sucrose	15 mg
30	starch	8 mg
	talc	4 mg
	stearic acid	2 mg

Example 3

(E)-1-[2-[4-[1-(4-Iodophenyl)-2-phenyl-1-butenyl]phenoxy]pyrrolidine, 50 mg, is dispersed in 25 ml of normal saline to prepare an injectable preparation.

What is claimed is:

1. A method of treating the symptoms of atrophic vaginitis and altered sexual behavior in postmenopausal women which comprises administering to a subject in need thereof an effective amount of a compound of formula I.
2. A method according to Claim 1 wherein the compound of formula I is (E)-1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]pyrrolidine.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/13460

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :AOIN 43/40 US CL :514/317, 315 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/317, 315 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
A	US 5,472,985 A (GRAINGER et al.) 05 December 1995, see entire document.	1 and 2																		
A	US 4,839,155 A (MCCAGUE) 13 June 1989, see entire document.	1 and 2																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
B earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 26 AUGUST 1998		Date of mailing of the international search report 16 SEP 1998																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer DWAYNE C. JONES Telephone No. (703) 308-1235																		

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/13460

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

REGISTRY, WPIDS, HCAPLUS, HCAOLD, EMBASE, MEDLINE, USPATFULL structure search with the following terms: disease or reperfusion, smithkline, idoxifen? or SB223030, ?menopaus? or cognit? or ?vagin? or behav?